Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors

NCT04242199 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04242199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04242199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 4, 2020
Completion date
November 21, 2024
Enrollment
182 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervical cancer, cutaneous squamous cell carcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, merkel cell carcinoma, mesothelioma, msi-h/dmmr tumors, nasopharyngeal carcinoma, pd-l1 amplified tumor (9p24.1), small-cell lung cancer, urothelial carcinoma